The clinical effectiveness initiative: a pharmacy analysis to improve outcomes and costs of drug therapy.
Selecting the most appropriate therapeutic regimens is one of the most complex and critical aspects of pharmacy management today, but the process is fraught with biases. Clinical pharmacists must offer balanced and unbiased opinions concerning therapies that provide the best cost-benefit ratio for their organizations. This article describes the use of existing administrative databases to develop robust clinical resource utilization data, identify internal bias and barriers to efficient drug therapy selection, and devise medical management strategies that provide desirable clinical outcomes through cost-consequence analysis.
Vogenberg
F Randy
FR
Aon Consulting, Life Sciences Practice, Providence, Rhode Island, USA.
Groce
James B
JB
Larrat
Paul
P
D003362:Cost-Benefit Analysis / Q000458:organization & administration*; D016527:Drug Costs; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome; D014481:United States; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D006495:Heparin, Low-Molecular-Weight